Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$23.27-0.7%$26.27$14.90▼$38.12$2.22B0.22960,164 shs701,469 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics0.00%-1.44%-11.08%-14.01%+27.58%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEWTXEdgewise Therapeutics1.9311 of 5 stars3.41.00.00.02.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.88Moderate Buy$45.3894.99% UpsideCurrent Analyst Ratings BreakdownLatest EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.003/4/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $56.001/22/2025EWTXEdgewise TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$30.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$100.16M-$1.45N/AN/AN/AN/A-26.83%-25.67%5/8/2025 (Estimated)Latest EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024EWTXEdgewise Therapeutics-$0.39-$0.42-$0.03-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A26.3526.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics24.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics6095.21 million71.86 millionOptionableEWTX HeadlinesRecent News About These CompaniesEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by American Century Companies Inc.March 31 at 3:30 AM | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Holdings Raised by Artisan Partners Limited PartnershipMarch 30 at 4:59 AM | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $45.38 Consensus Price Target from BrokeragesMarch 30 at 1:17 AM | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Trading Up 9.3% - Should You Buy?March 28 at 12:17 PM | marketbeat.comEFG Asset Management North America Corp. Takes $1.10 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)March 27, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Recommendation of "Moderate Buy" by BrokeragesMarch 27, 2025 | marketbeat.comEdgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern TimeMarch 26, 2025 | prnewswire.comRelative Strength Alert For Edgewise TherapeuticsMarch 26, 2025 | nasdaq.comTruist Financial Keeps Their Buy Rating on Edgewise Therapeutics (EWTX)March 24, 2025 | markets.businessinsider.comIntech Investment Management LLC Buys 14,944 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)March 24, 2025 | marketbeat.comTruist maintains Buy rating on Edgewise Therapeutics stockMarch 23, 2025 | uk.investing.comVictory Capital Management Inc. Purchases Shares of 21,568 Edgewise Therapeutics, Inc. (NASDAQ:EWTX)March 22, 2025 | marketbeat.comEWTX Makes Notable Cross Below Critical Moving AverageMarch 21, 2025 | nasdaq.comPiper Sandler Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)March 21, 2025 | markets.businessinsider.comCharles Schwab Investment Management Inc. Purchases 15,273 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)March 21, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.5% - Should You Sell?March 20, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Time to Sell?March 18, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Position Lifted by AmundiMarch 15, 2025 | marketbeat.comEdgewise Therapeutics (EWTX) Gets a Buy from WedbushMarch 13, 2025 | markets.businessinsider.comEdgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.3% - Time to Sell?March 13, 2025 | marketbeat.comEdgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific ConferenceMarch 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEWTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$23.27 -0.17 (-0.73%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$24.30 +1.03 (+4.44%) As of 03/28/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
